China's Foreign Ministry has condemned the recently passed Biosecure Act by the U.S. House of Representatives, which seeks to prohibit federal contracts with several Chinese biotech companies, including BGI and WuXi AppTec, labeling the action as unwarranted oppression. The bill, which passed overwhelmingly with a vote of 306 to 81, is viewed by critics, including House Democrat Jim McGovern, as discriminatory and lacking due process. While the legislation has significant momentum, a divide among Democrats may complicate its passage in the Senate, where some members express concerns over singling out companies. The targeted firms have denied any national security threats and claimed the legislation is based on false allegations, asserting they do not access U.S. citizens' personal data. Chinese officials urged the U.S. to abandon ideological bias and create a fair business environment. This legislation is part of a broader trend of U.S. bills aimed at addressing concerns related to China in various sectors, including trade and technology.